Capricor Therapeutics is trading 23.1% higher at $10.55 after HOPE-3 extension findings reported slower upper-limb and elbow-function decline among patients who switched from placebo to deramiocel. - Findings were presented at the World Muscle Society Congress. The company had announced the presentation in advance, but its release did not include the new numerical findings. - Prior HOPE-3 results showed 54% slower upper-limb decline versus placebo over 12 months; the extension presentation adds longer-term evidence. - The stock closed at $8.57 on September 29.